Co-Authors
This is a "connection" page, showing publications co-authored by MIEN-CHIE HUNG and SEUNG-OE LIM.
Connection Strength
3.841
-
Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016 Dec 12; 30(6):925-939.
Score: 0.598
-
EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Res. 2016 Mar 01; 76(5):1284-96.
Score: 0.564
-
Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. J Biol Chem. 2022 04; 298(4):101817.
Score: 0.216
-
TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest. 2021 04 15; 131(8).
Score: 0.203
-
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019 07 15; 129(8):3324-3338.
Score: 0.180
-
Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. Am J Cancer Res. 2018; 8(9):1837-1846.
Score: 0.169
-
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018 08 16; 71(4):606-620.e7.
Score: 0.169
-
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018 05 15; 9(1):1908.
Score: 0.166
-
Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell. 2018 04 09; 33(4):752-769.e8.
Score: 0.164
-
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell. 2018 02 12; 33(2):187-201.e10.
Score: 0.163
-
Rational combination of immunotherapy for triple negative breast cancer treatment. Chin Clin Oncol. 2017 Oct; 6(5):54.
Score: 0.159
-
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017 Jul 15; 23(14):3711-3720.
Score: 0.152
-
GSK3? inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget. 2016 Aug 30; 7(35):57131-57144.
Score: 0.147
-
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632.
Score: 0.147
-
Extracellular PKM2 induces cancer proliferation by activating the EGFR signaling pathway. Am J Cancer Res. 2016; 6(3):628-38.
Score: 0.142
-
AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res. 2016 Mar 15; 76(6):1451-62.
Score: 0.141
-
EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature. 2013 May 16; 497(7449):383-7.
Score: 0.117
-
Epithelial-mesenchymal transition induced by TNF-a requires NF-?B-mediated transcriptional upregulation of Twist1. Cancer Res. 2012 Mar 01; 72(5):1290-300.
Score: 0.107
-
Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors. Biochem Biophys Res Commun. 2011 Jan 07; 404(1):68-73.
Score: 0.099
-
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ?-blockers. Sci Transl Med. 2017 Nov 08; 9(415).
Score: 0.040